Ascendis製藥 ASND 深 滬
等待開盤 02-06 09:30:00 美东时间
217.38
-2.350
-1.07%
華盛通- 最 高227.18
- 今 開220.31
- 成交量 133.14万股
- 最 低 215.51
- 昨 收 219.73
- 總市值 134.11亿
- 52周最高 242.00
- 市盈率 靜 --
- 換手率 2.16%
- 52周最低 124.06
- 委 比 -13.04%
- 總股本 6169.52万
- 歷史最高 242.00
- 量 比 2.77
- 振 幅 5.31%
- 歷史最低 11.92
- 每 手 1
- 風險率 25.43%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 苹果、SanDisk、西部数据、卡特彼勒、德克斯户外、霍尼韦尔、西南航空、万事达等获多家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Praxis Precision Medicine"买入"评级，目标价从340美元升至1245美元；HC Wainwright & Co.：维持Perspective Therapeutics"买入"评级，目标价从10美元升至12美元
02-02 14:15
美股大行评级 | 希捷科技、德州仪器、HCA控股、通用汽车、波音、UPS等或多家机构上调目标价；布朗保险、康沃系统、Qorvo、联合健康等遭多家机构下调目标价
今日重点评级关注：Piper Sandler：维持Praxis Precision Medicine"超配"评级，目标价从450美元升至1200美元；Tigress Financial：维持Main International ETF"买入"评级，目标价从52美元升至66美元
01-29 11:06
Barclays Initiates Coverage On Ascendis Pharma with Overweight Rating, Announces Price Target of $342
Barclays analyst Eliana Merle initiates coverage on Ascendis Pharma (NASDAQ:ASND) with a Overweight rating and announces Price Target of $342.
01-28 22:33
Ascendis Pharma rises amid takeover speculation
Ascendis Pharma (ASND) gained 7.5% amid some takeover speculation. There's talk that a Switzerland-based pharma company and another European firm are eyeing Ascendis (ASND), according to traders, who ...
01-23 00:47
美股大行评级 | 存储再获大行看好！花旗、瑞银和美银齐上调西部数据、希捷科技等公司目标价；PNC金融服务获6家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Soleno Therapeutics"买入"评级，目标价从110美元升至120美元；富国银行：维持Soleno Therapeutics"超配"评级，目标价从106美元升至114美元
01-21 11:42
Wells Fargo Maintains Overweight on Ascendis Pharma, Raises Price Target to $330
Wells Fargo analyst Derek Archila maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and raises the price target from $322 to $330.
01-20 23:48
美股大行评级 | 瑞穗上调英伟达、谷歌、美光科技、SanDisk多家科技股目标价；中金首予诺和诺德"跑赢大市"评级，目标价73.5美元
今日重点评级关注：Needham：维持Cartesian Therapeutics"买入"评级，目标价从40美元升至42美元；Piper Sandler：维持Acrivon Therapeutics"超配"评级，目标价从6美元升至8美元
01-12 14:09
Week 52 COACH Trial Topline Results Confirm Consistent and Durable Treatment Benefits in Children with Achondroplasia (ACH)
<p><p>Ascendis Pharma announced Phase 2 COACH trial results showing that once-weekly TransCon CNP and TransCon hGH combination therapy in children with achondroplasia demonstrated durable growth, improved body proportionality, and exceeded 97th-percentile annualized growth velocity without compromising safety or tolerability at 52 weeks. The combination therapy also improved arm span beyond the 84th percentile and maintained bone age. All childre...
01-08 21:01
美股大行评级 | 瑞银上调美光科技目标价从300美元升至400美元；Freedom上调百度目标价从120美元升至160美元
今日重点评级关注：Needham：维持Vaxcyte"买入"评级，目标价从90美元升至110美元；Citizens: 维持LGI Homes"跑赢大市"评级，目标价从85美元升至95美元
01-08 18:33
TD Cowen Reiterates Buy on Ascendis Pharma, Maintains $325 Price Target
TD Cowen analyst Yaron Weber reiterates Ascendis Pharma (NASDAQ:ASND) with a Buy and maintains $325 price target.
01-07 23:48
